In the Asia-Pacific pharmaceutical industry, there were 18 private equity deals announced in Q2 2023, worth a total value of $4.5bn, according to GlobalData’s Deals Database. The $2bn institutional buy-out (ibo) manipal health enterprises by Temasek Holdings (Private) was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Asia-Pacific increased by 246% in Q2 2023 compared with the previous quarter’s total of $1.3bn and rose by 251% as compared to Q2 2022. Related deal volume increased by 38% in Q2 2023 versus the previous quarter and was 80% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in Asia-Pacific in Q2 2023 were Maybank Securities; UBS Group; Nine Rivers Capital Holdings with 2, 2, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Asia-Pacific Q2 2023 were King & Spalding; Milbank; White & Case with 2, 2, 2 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Smarter leaders trust GlobalData
Premium Insights Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence
Premium Insights
The gold standard of business intelligence.
